Lisanti Capital Growth LLC Increases Stake in GeneDx Holdings Corp. $WGS

Lisanti Capital Growth LLC raised its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 92.3% during the second quarter, HoldingsChannel reports. The firm owned 56,615 shares of the company’s stock after purchasing an additional 27,180 shares during the period. GeneDx comprises 1.4% of Lisanti Capital Growth LLC’s portfolio, making the stock its 21st largest holding. Lisanti Capital Growth LLC’s holdings in GeneDx were worth $5,226,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of WGS. US Bancorp DE boosted its position in GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after acquiring an additional 548 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after purchasing an additional 594 shares during the last quarter. PNC Financial Services Group Inc. purchased a new stake in shares of GeneDx during the 1st quarter worth $132,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in GeneDx by 184.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,224 shares of the company’s stock valued at $197,000 after purchasing an additional 1,443 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in GeneDx in the second quarter valued at about $204,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Price Performance

NASDAQ WGS opened at $139.73 on Friday. The stock’s fifty day moving average price is $125.41 and its 200 day moving average price is $100.49. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $146.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The company has a market cap of $4.01 billion, a price-to-earnings ratio of 1,552.56 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The business had revenue of $116.74 million for the quarter, compared to analyst estimates of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. Wells Fargo & Company increased their price objective on GeneDx from $95.00 to $140.00 and gave the company an “equal weight” rating in a report on Tuesday, November 4th. Canaccord Genuity Group set a $160.00 target price on GeneDx and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, BTIG Research raised their price target on GeneDx from $140.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $129.22.

Insider Buying and Selling at GeneDx

In other news, CEO Katherine Stueland sold 2,158 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $136.54, for a total value of $294,653.32. Following the sale, the chief executive officer directly owned 3,436 shares of the company’s stock, valued at $469,151.44. This represents a 38.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin Feeley sold 388 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $52,977.52. Following the completion of the sale, the chief financial officer owned 3,757 shares in the company, valued at $512,980.78. The trade was a 9.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 556,375 shares of company stock valued at $67,569,247. 29.60% of the stock is currently owned by insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.